Nitin Joshi, PhD, and Jingjing Gao, PhD, of the Department of Anesthesiology at Mass General Brigham, are the co-senior ...

Aperture Therapeutics is advancing APRTX-003, an RNA-based antisense therapy targeting MMP9, as a potential ALS treatment.

Osteoarthritis is a highly prevalent joint disease that leads to cartilage breakdown, pain and disability, yet there are ...

Pancreatic ductal adenocarcinoma (PDAC) is the most lethal form of pancreas cancer. It's also the most common form of the ...

Researchers have developed a nanoparticle platform that can deliver mRNA therapy to affected cartilage based on ...

Bayer and Soufflé Therapeutics™, an innovative biotech company that discovers and develops cell-selective genetic therapies, ...

Ionis Pharmaceuticals’ launch of Tryngolza (olezarsen) is off to a flying start as a treatment for familial chylomicronemia syndrome (FCS). | Ionis Pharmaceuticals’ launch of Tryngolza (olezarsen) is ...

We recently published 10 Shares Explode as Earnings Impress. Avidity Biosciences, Inc. (NASDAQ:RNA) is one of the best-performing stocks on Friday. Avidity Biosciences saw its share prices increase by ...

A specially engineered antibody capable of delivering RNA therapies to hard-to-reach, treatment-resistant tumors significantly shrank tumor size and improved survival in animal models, according to a ...

In adults with chronic hepatitis B infection receiving viral suppression therapy, coupling an investigational small interfering RNA therapy with an immunomodulator led to substantial declines in blood ...